The baseline prevalence of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection among 2705 patients enrolled in HIV clinical trials in the Community Programs for Clinical Research on AIDS (CPCRA) was 16.6%. For men, multivariate logistic regression showed that the baseline prevalence of HIV-HCV coinfection was positively associated with history of injection drug use, older age, antiretroviral therapy naive status, African American or Latino ethnicity, and no history of having sex with men. No association was found with baseline CD4+ cell count or HIV RNA level. The prevalence of HCV coinfection in a diverse HIV clinical trials cohort provides additional information about risk behaviors and demographic factors that can be used in the analysis of clinical and virologic outcomes.
CITATION STYLE
Tedaldi, E. M., Huppler Hullsiek, K., Malvestutto, C. D., Arduino, R. C., Fisher, E. J., Gaglio, P. J., … Perez, G. (2003). Prevalence and characteristics of hepatitis C virus coinfection in a human immunodefidency virus clinical trials group: The Terry Beirn Community Programs for Clinical Research on AIDS. Clinical Infectious Diseases, 36(10), 1313–1317. https://doi.org/10.1086/374841
Mendeley helps you to discover research relevant for your work.